{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T21:34:26Z","timestamp":1776288866201,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"S4","license":[{"start":{"date-parts":[[2015,6,8]],"date-time":"2015-06-08T00:00:00Z","timestamp":1433721600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Galderma Laboratorium GmbH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Acne is a chronic inflammatory disease requiring long\u2010term treatment. The fixed\u2010dose combination adapalene 0.1%\/benzoyl peroxide 2.5% (adapalene\u2010<jats:styled-content style=\"fixed-case\">BPO<\/jats:styled-content>) is indicated for the once\u2010daily topical treatment of Acne vulgaris when comedones, papules and pustules are present.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The main objectives of this non\u2010interventional study were to assess long\u2010term efficacy and safety of adapalene\u2010<jats:styled-content style=\"fixed-case\">BPO<\/jats:styled-content> in moderate to severe acne with and without concomitant medication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with moderate to severe acne received adapalene\u2010<jats:styled-content style=\"fixed-case\">BPO<\/jats:styled-content> alone or in combination with concomitant medication over a course of 9\u00a0months. The primary efficacy endpoint was changes in acne severity according to the Leeds Revised Acne Grading System; secondary endpoints included treatment success assessed by the patient and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 5131 patients were eligible for efficacy and 5141 for safety evaluation. The majority of patients (78.8%) received adapalene\u2010<jats:styled-content style=\"fixed-case\">BPO<\/jats:styled-content> alone. About 21.2% received adapalene\u2010<jats:styled-content style=\"fixed-case\">BPO<\/jats:styled-content> in combination with another agent, mostly topical antibiotics (8.8%) or systemic antibiotics (8.7%). Mean (\u00b1SD) acne severity improved from 5.6\u00a0\u00b1\u00a01.5 at baseline to 3.3\u00a0\u00b1\u00a01.9 at month 3, and further to 1.9\u00a0\u00b1\u00a01.9 at month 9 (both <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001). The degree of improvement correlated significantly with the severity at baseline. After 3 and 9\u00a0months of treatment, the facial skin was cleared completely (no more visible acne lesions) in 420 (8.2%) and 1326 patients (25.8%), respectively. A therapeutic effect was noted by the patients after a median time of 3\u00a0weeks (range: from 1\u00a0day to 12\u00a0weeks). No serious adverse events were reported. Facial skin irritations, mostly mild to moderate, occurred in 49.5% of patients and led to discontinuation in only 1.7% of cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In consistence with previous clinical findings, the use of adapalene\u2010<jats:styled-content style=\"fixed-case\">BPO<\/jats:styled-content> in daily practice routine is safe and effective in the long\u2010term management of patients with moderate to severe acne.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.13194","type":"journal-article","created":{"date-parts":[[2015,6,11]],"date-time":"2015-06-11T01:34:58Z","timestamp":1433986498000},"page":"15-22","source":"Crossref","is-referenced-by-count":12,"title":["Safety and efficacy of adapalene 0.1% \/ benzoyl peroxide 2.5% in the long\u2010term treatment of predominantly moderate acne with or without concomitant medication \u2013 results from the non\u2010interventional cohort study <scp>ELANG<\/scp>"],"prefix":"10.1111","volume":"29","author":[{"given":"H.P.M.","family":"Gollnick","sequence":"first","affiliation":[{"name":"Department of Venerology and Dermatology Otto\u2010von\u2010Guericke University Magdeburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Friedrich","sequence":"additional","affiliation":[{"name":"Dermatologist in Private Practice Oranienburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Peschen","sequence":"additional","affiliation":[{"name":"Dermatologist in Private Practice Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Pettker","sequence":"additional","affiliation":[{"name":"Dermatologist in Private Practice Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pier","sequence":"additional","affiliation":[{"name":"Dermatologist in Private Practice Lippstadt Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Streit","sequence":"additional","affiliation":[{"name":"Dermatologist in Private Practice Buchholz in der Nordheide Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"J\u00f6stingmeyer","sequence":"additional","affiliation":[{"name":"Med:Unit GmbH K\u00f6ln Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Porombka","sequence":"additional","affiliation":[{"name":"Galderma Laboratorium GmbH D\u00fcsseldorf Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Rojo Pulido","sequence":"additional","affiliation":[{"name":"Galderma Laboratorium GmbH D\u00fcsseldorf Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"J\u00e4ckel","sequence":"additional","affiliation":[{"name":"Galderma Laboratorium GmbH D\u00fcsseldorf Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,6,8]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"4","article-title":"Physiopathology of acne vulgaris: recent data, new understanding of the treatments","volume":"14","author":"Pawin H","year":"2004","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.01.019"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmh407"},{"key":"e_1_2_6_5_1","first-page":"459","article-title":"Inflammation and acne: putting the pieces together","volume":"13","author":"Harvey A","year":"2014","journal-title":"J Drugs Dermatol"},{"issue":"8","key":"e_1_2_6_6_1","first-page":"s109","article-title":"The sequence of inflammation, relevant biomarkers, and the pathogenesis of acne vulgaris: what does recent research show and what does it mean to the clinician?","volume":"12","author":"Del Rosso JQ","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000087011"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.1390s2003.x"},{"key":"e_1_2_6_9_1","first-page":"22","article-title":"Tretinoin: A review of its anti\u2010inflammatory properties in the treatment of acne","volume":"4","author":"Schmidt N","year":"2011","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2007.00552.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2011.01339.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2010.07466.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.618"},{"key":"e_1_2_6_14_1","first-page":"899","article-title":"Long\u2010term safety and efficacy of a unique fixed\u2010dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris","volume":"6","author":"Pariser DM","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.06.006"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09209.x"},{"key":"e_1_2_6_17_1","first-page":"110","article-title":"A North American study of adapalene\u2010benzoyl peroxide combination gel in the treatment of acne","volume":"84","author":"Gold LS","year":"2009","journal-title":"Cutis"},{"key":"e_1_2_6_18_1","first-page":"1395","article-title":"Treatment of 2453 acne vulgaris patients aged 12\u201317\u00a0years with the fixed\u2010dose adapalene\u2010benzoyl peroxide combination topical gel: efficacy and safety","volume":"9","author":"Eichenfield LE","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04374.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sder.2010.04.002"},{"key":"e_1_2_6_21_1","first-page":"611","article-title":"Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene\u2010benzoyl peroxides","volume":"12","author":"Eichenfield LF","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_22_1","first-page":"174","article-title":"Short\u2010term combination therapy and long\u2010term relapse prevention in the treatment of severe acne vulgaris","volume":"11","author":"Tan J","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13191"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10344.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000350820"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546639809160698"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200809050-00001"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12613"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.03.036"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546631003681094"},{"key":"e_1_2_6_31_1","first-page":"1331","article-title":"A call to limit antibiotic use in acne","volume":"12","author":"Thiboutot D","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2007.01.001"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2014.26.1.43"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13194","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13194","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T08:07:21Z","timestamp":1694592441000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.13194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":32,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1111\/jdv.13194"],"URL":"https:\/\/doi.org\/10.1111\/jdv.13194","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}